Loading…
← CockpitCompetitor Analysis › BNTX BioNTech SE Sponsored ADROpen in the cockpit ↗

BioNTech SE Sponsored ADRBNTXCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

German mRNA biotech that co-developed the Pfizer-BioNTech COVID vaccine, now focused on mRNA and antibody cancer therapies.

Momentum weak 30
Mkt cap
$20.6B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$85.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-39.2 pp
WACC 11.3%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$83.26
1D-1.9%
1W-5.0%
1M-8.7%
3M-24.9%
6M-7.9%
YTD-12.5%
1Y-18.9%
ATR %3.1%
Beta0.96
52w lowhigh32.9% off high

What BioNTech SE Sponsored ADR does

German mRNA biotech that co-developed the Pfizer-BioNTech COVID vaccine, now focused on mRNA and antibody cancer therapies.

Most revenue still comes from the COVID-19 vaccine Comirnaty, which Pfizer sells in most markets and the two share the profit on, while BioNTech sells it itself in Germany and Turkey. Its cancer drugs are not yet approved, and in 2025 it agreed to co-develop an antibody cancer drug with Bristol Myers Squibb.

Products and services

  • Comirnaty (COVID-19 vaccine, with Pfizer)
  • Oncology pipeline (individualized mRNA cancer vaccines)
  • Antibody-drug conjugates (partnered programs)

Customers

  • Governments/public health systems (vaccine)
  • Oncologists (pipeline, future)

Where it sits in the supply chain

  • Healthcare
  • Biotechnology
  • mRNA and immunotherapy drug discovery…

What could go right

  • Oncology pipeline data readouts
  • Diversification beyond COVID vaccine revenue

What could go wrong

  • Steep COVID vaccine revenue decline
  • Binary clinical trial risk in oncology pipeline

Moat: narrow (IP / patents, process know-how). Pioneering mRNA platform IP and manufacturing scale, though pipeline value remains largely unproven outside COVID.

Headquarters: Mainz, Germany · Founded: 2008 · Employees: 7,807

Named competitors

BioNTech SE Sponsored ADR at a glance

Size BioNTech SE Sponsored ADR (BNTX) is a United States Health Care company (Biotechnology) with a market value of $20.6B, the 482nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $83.26 on 18 Nov 2026.

Performance Over six months the shares fell 7.9%, against +26.1% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue fell 20.7% over the last twelve months (peer median +25.2%); the operating margin is -61.2% (peer median 24.6%).

Valuation It trades at 1.9× enterprise value to sales against a peer median of 8.4× (cheapest of 20).

Capital Return on invested capital runs 39.2 points below its cost of capital (11.3% WACC).

Short interest Short interest is 0.9% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 124BNTX 92
Six months, rebased to 100: BioNTech SE Sponsored ADR against the median of its 20 peers (local-currency closes).

BioNTech SE Sponsored ADR financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.80B$3.24B$2.98B$4.13B$18.2B
Revenue growth—+9%-28%-77%—
Gross profit$1.43B$2.51B$2.39B$3.51B$18.0B
EBITDA-$688M-$301M-$374M$1.18B$16.1B
Net income-$1.72B-$1.28B-$720M$1.01B$9.92B
Free cash flow-$518M$317M-$265M$5.54B$13.9B
Capital expenditure$287M$845M$489M$763M$382M
Total debt$576M$314M$263M$242M$226M

Quarterly statements and history in the cockpit →

BioNTech SE Sponsored ADR competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%2269UTHRNBIXBBIOGMABELAN0682701093BMRNTECHHALOKYMRNTRA002422IQVKRYSPCVX1961702079401548BNTX6-month return →1-month return →
Up and to the right = strong over both horizons. BioNTech SE Sponsored ADR is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×50×2269UTHRNBIXBBIOGMABELAN068270HALOKYMRNTRAKRYS196170207940BNTXRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. BioNTech SE Sponsored ADR is the large dot.

BioNTech SE Sponsored ADR competitors and peer comparison

Head to head with its named competitors (BNTX vs MRNA vs PFE vs RO.SW)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
BioNTech SE Sponsored ADR BNTX$20.6B-8%-21%-61%1.9×n/a
Moderna MRNA$79.6B+309%+13%-116%31.2×n/a
Pfizer PFE$160B+9%+1%26%3.3×-4.3%
Roche RO.SW$381B+21%-1%31%5.7×1.7%

How BioNTech SE Sponsored ADR compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

BioNTech SE Sponsored ADR against its 20 peers (data as of 18 Nov 2026)
MeasureBNTXPeer medianRank in peer set
1-month return-8.7%-2.0%7th lowest of 21
6-month return-7.9%+26.1%2nd lowest of 21
Distance from 52-week high-32.9%-17.0%5th lowest of 21
Revenue growth (TTM)-20.7%+25.2%lowest of 20
Operating margin-61.2%24.6%2nd lowest of 20
EV / Sales1.9×8.4×cheapest of 20
ROIC minus cost of capital-39.2 pp+0.3 pp3rd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
BioNTech SE Sponsored ADR BNTXUnited States$20.6B-8%-21%-61%1.9×n/an/a
Wuxi Bio 2269.HKHong Kong$23.1B+35%+22%32%6.7×20.8%+30.2%
United Therapeutics UTHRUnited States$24.6B+2%+2%44%7.1×0.3%+16.5%
Neurocrine Biosciences NBIXUnited States$16.5B+5%+38%25%4.4×-1.5%+22.3%
BridgeBio Pharma BBIOUnited States$15.2B+14%+167%-37%19.1×n/an/a
Genmab A/S GMAB.CODenmark$30.8B+103%+15%31%8.4×11.6%+19.5%
Elanco Animal Health ELANUnited States$13.3B+28%+12%8%3.2×32.9%+7.6%
Celltrion 068270.KSSouth Korea$34.9B+12%+40%32%9.0×10.6%+17.6%
Cspc Pharma 1093.HKHong Kong$12.0B+10%+25%28%2.1×-10.7%+0.1%
BioMarin Pharmaceutical BMRNUnited States$11.9B+22%+20%19%4.2×8.2%+12.0%
Bio-Techne TECHUnited States$11.4B+56%+1%21%9.2×31.6%+5.5%
Halozyme Therapeutics HALOUnited States$10.9B+39%+45%57%7.3×-0.3%+39.2%
Kymera Therapeutics KYMRUnited States$10.3B+50%+134%-396%92.4×n/an/a
Natera NTRAUnited States$42.0B+41%+37%-9%14.1×n/an/a
Sichuan Kelun Pharmaceutical 002422.SZChina$10.1B+35%0%9%3.7×6.2%+2.3%
Iqvia IQVUnited States$42.5B+50%+9%14%3.3×16.8%+7.5%
Krystal Biotech KRYSUnited States$9.34B+4%+26%48%18.0×13.1%+26.0%
Vaxcyte PCVXUnited States$9.26B+24%n/an/an/an/an/a
ALTEOGEN 196170.KSSouth Korea$8.80B-56%+61%53%35.1×24.6%+38.5%
Samsung Biologics 207940.KSSouth Korea$48.7B-6%-20%43%14.5×7.0%+31.4%
Genscript Biotech 1548.HKHong Kong$8.69B+133%+53%12%9.8×36.9%+19.8%

Questions

Who are BioNTech SE Sponsored ADR's main competitors?
Named competitors: Moderna (MRNA), Pfizer (PFE), Roche (RO.SW). The cockpit's measured peer set (industry) also includes Wuxi Bio (2269.HK), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BridgeBio Pharma (BBIO), Genmab A/S (GMAB.CO), Elanco Animal Health (ELAN).
Is BioNTech SE Sponsored ADR expensive compared with its peers?
On ev / sales it trades at 1.9× against a peer median of 8.4×, cheapest of 20 in its peer set.
How has BioNTech SE Sponsored ADR stock performed?
Over six months to 18 Nov 2026 the shares returned -7.9% against +26.1% for the median peer; over one year -18.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.